NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

AF looked the fool and the shorts lost huge when DNDN's trial results showed it extended patient's survival significantly (btw, for anyone reading--when 'significantly' is said in academia, it doesn't mean "by a whole lot!" like it's used casually--it means simply a statistically significant result, implying nothing about the extent of the effect). Then much later the vaccine was finally approved (http://www.dailyfinance.com/2010/04/29/dendreons-prostate-cancer-vaccine-approved-shares-soar-before/). Pretty sure that's what he's referring to.

At that point a handful may have seen how competitive the landscape truly was, and once Zytiga came along (soon after), Provenge was blown away before they could even ramp up manufacturing capability. Ultimately, a therapy that doesn't sell isn't worth anything, regardless of approval. Of course, that is where Provenge and DCVax-L part ways, and at that by 100 miles (not to mention extent of effect above SOC likely being much greater with DCVax-L).